On Thursday, September 28, an FDA Advisory Committee will review ataluren for potential approval and use within our Duchenne community. The Duchenne community is joining forces in a show of strength to demonstrate to the FDA our community’s support for our robust therapeutic pipeline. This is our community’s opportunity to once again stand up and share our stories and our experiences with a the…